Form 4: Syra Health Corp Director Acquires Stock Options

A Syra Health Corp director, Sherron Rogers, acquired 11,581 stock options on November 14, 2024, under the company's 2022 Omnibus Equity Incentive Plan.

Summary

• Sherron Rogers, a director at Syra Health Corp, acquired 11,581 stock options on November 14, 2024.
• The options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• The exercise price of the options is $0.3683 per share.
• 25% of the options vested immediately upon grant, and the remaining options will vest in 12 equal monthly installments.
• The options expire on November 14, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to directors, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Future Outlook

The remaining options will vest in 12 equal monthly installments.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with shareholders in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies.
• The vesting schedule of 25% immediately and the remainder over 12 months is a typical vesting structure.
• The 10-year expiration period is also a standard practice for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence due to the alignment of director interests with company performance.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, director, Syra Health Corp, SYRA